SCHEMBL9907414

SCHEMBL9907414

O=C(O)c1cc(Cl)c2nccc(O)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 4/20 0.47
KMO O15229 1/20 0.44
TSHR P16473 1/20 0.42
TPMT P51580 1/20 0.41
KDM4E B2RXH2 4/20 0.41
KDM4A O75164 3/20 0.41
EGLN1 Q9GZT9 2/20 0.41
HIF1AN Q9NWT6 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
RAB9A P51151 1/20 0.41
KDM4C Q9H3R0 5/20 0.40
KDM5A P29375 3/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
KDM6B O15054 2/20 0.40
KDM5C P41229 2/20 0.40
KDM2A Q9Y2K7 2/20 0.40
KDM3A Q9Y4C1 2/20 0.40
KDM5B Q9UGL1 2/20 0.40
TET3 O43151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907415 0.82 KDM4E (0.46) TPMTKDM4EL3MBTL1KDM4CALDH1A1
SCHEMBL9104437 0.81 KDM4E (0.41) TTRTPMTKDM4EKDM4AEGLN1
SCHEMBL9907435 0.81 KDM4E (0.41) TTRKDM4EKDM4AEGLN1HIF1AN
SCHEMBL11007450 0.78 MAPT (0.44) TSHRKDM4EL3MBTL1ALDH1A1MAPT
SCHEMBL30351236 0.78 MAPT (0.44) TSHRKDM4EL3MBTL1ALDH1A1MAPT
SCHEMBL9907439 0.77 SLC6A2 (0.38) KMOKDM4EKDM4AEGLN1HIF1AN
SCHEMBL9907427 0.75 RORC (0.39) TTRKMOKDM4AKDM4CKDM5A
SCHEMBL19893538 0.73 TTR (0.48) TTRKMOTSHRTPMTKDM4E
SCHEMBL23166686 0.72 PTPN6 (0.50) TTRTSHRL3MBTL1ALDH1A1MAPT
SCHEMBL14332932 0.71 KDM4E (0.47) KDM4EKDM4AEGLN1HIF1ANL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E TTR 3634/4885KMO 559/4885TSHR 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.